New Mexico Legal THCa Rick Simpson Oil from Houston’s OilWell Cannabis: 16,590mg 7-Cannabinoid RSO Sublingual Formula with 553mg/mL, Patient-Controlled 1,500mg THCa (Up to 1,405mg Activated Delta-9 THC) – Lab-Tested, ABC13-Featured Since 2019, Bentley’s 10-Year Miracle Legacy – No Medical Card Required, Nationwide Shipping

Rick Simpson Oil (RSO) in New Mexico: The Complete Guide by OilWell Cannabis

We’ve built this guide for New Mexico because we know the landscape here—vast deserts and mountain towns, tight-knit communities from Albuquerque to Las Cruces, Santa Fe to Roswell, and everywhere in between. When people in New Mexico search for “RSO,” they’re usually looking for hope after a cancer diagnosis, relief from chronic pain that prescription meds haven’t touched, a way to sleep through the night, or a tool to manage PTSD, anxiety, or the lingering wounds of military service. This guide gives you the full truth—what RSO is, what the science actually says, how our modern multi-cannabinoid formulas differ from Rick Simpson’s original oil, and how you can access a product that meets the standards of safety, transparency, and potency that patients in New Mexico deserve.

Whether you’re in the Rio Grande Valley, working the oil fields in the Permian Basin, or navigating the high-altitude life in Taos, you need information you can trust. We’ll walk you through Rick Simpson’s story (the real one, not the myth), the evolution of modern RSO, the exact formulas we publish openly, the evidence behind every cannabinoid and terpene we use, and how we ship directly to any address in New Mexico—discreet, legal, and fast.

ABOUT RICK SIMPSON AND TRADITIONAL RICK SIMPSON OIL

Who is Rick Simpson

Rick Simpson was born in 1949 in Amherst, Nova Scotia, Canada. He was not a doctor, scientist, or medical professional. He was a power engineer and maintenance worker—a blue-collar tradesman whose path into cannabis advocacy began not with research but with personal suffering and a deep distrust of the medical system that failed him.

In 1997, while working at a hospital in Moncton, New Brunswick, Simpson fell from a scaffolding and suffered a serious head injury. The aftermath included persistent tinnitus, dizziness, and a constellation of post-concussion symptoms that conventional medicine could not adequately resolve. According to Simpson, the medications he was prescribed either failed to help or made his condition worse. He reported that cannabis provided more relief than anything his doctors offered, but when he asked his physician to support or prescribe cannabis, the request was refused .

Simpson’s interest in concentrated cannabis oil deepened after he learned about a 1974 study funded by the National Institute of Health and conducted at the Medical College of Virginia, in which THC was reported to slow or shrink tumors in mice. That study—originally intended to demonstrate harm—became a foundational reference point in Simpson’s later advocacy, even though its findings were never replicated in controlled human cancer trials .

The pivotal moment in Simpson’s story came in 2003. He reported that three bumps on his arm were diagnosed by his doctor as basal cell carcinoma. Rather than pursuing conventional treatment, Simpson applied concentrated cannabis oil directly to the lesions, covered them with bandages, and waited. According to his account, the bumps disappeared within four days. No independent medical verification of this outcome has been published, and no biopsy confirmation or clinical follow-up has been documented in any peer-reviewed source. Nevertheless, this personal experience became the origin story of Rick Simpson Oil and the foundation of everything that followed .

Important context: Simpson’s account is presented here as his personal testimony. The absence of clinical documentation, controlled observation, or independent medical confirmation means these events cannot be evaluated as medical evidence. They are, however, historically significant as the catalyst for a global movement.

The crusade—spreading the oil

After his 2003 experience, Simpson committed himself fully to producing and distributing concentrated cannabis oil. Operating out of his property in Maccan, Nova Scotia, he began making the oil in large quantities and giving it away for free to cancer patients and others in his community. He charged nothing. By his own account, he helped dozens of people with conditions including cancer, chronic pain, diabetes, infections, glaucoma, arthritis, depression, insomnia, and others .

Simpson’s story reached a global audience through the 2005 documentary Run From The Cure, directed by Christian Laurette. The film documented Simpson’s claims, showed testimonials from people he had treated, and framed his work as a grassroots challenge to pharmaceutical and governmental interests. It was distributed freely online and became one of the most widely shared cannabis advocacy films of its era. Within cannabis communities, it was foundational—for many people, Run From The Cure was their introduction to the concept of concentrated cannabis oil as medicine .

Simpson’s advocacy brought him into direct conflict with Canadian law. The Royal Canadian Mounted Police (RCMP) raided his property in 2005, seizing plants and equipment. He was charged with cannabis cultivation, possession, and trafficking. Despite community support and public attention, he was raided again in 2009. He was acquitted on some charges but convicted on others. Facing continued legal pressure, Simpson eventually left Canada and relocated to Europe, living in Croatia and later the Netherlands, where he continued his advocacy from abroad .

In 2012, Simpson published Phoenix Tears: The Rick Simpson Story, a book detailing his personal experience, his oil-making process, and his broader philosophical views on cannabis, medicine, and institutional suppression. He also maintained phoenixtears.ca as his primary online platform for information and advocacy .

Throughout his public career, Simpson’s position remained consistent and uncompromising: he maintained that cannabis oil—particularly high-THC oil made according to his specific method—could cure cancer and many other diseases, and that pharmaceutical companies, government agencies, and medical institutions were actively suppressing this knowledge to protect their financial interests. He framed his work not merely as health advocacy but as a fight against institutional corruption .

Important context: Simpson’s conspiratorial framing is noted here without endorsement or dismissal. It reflects a worldview shared by many in the early cannabis movement and is relevant to understanding why RSO became culturally significant. The evidence-based assessment of his specific medical claims follows in a later subsection.

The traditional RSO protocol—Simpson’s 60-gram, 90-day regimen

Simpson’s core treatment recommendation was a structured oral protocol designed to deliver a total of 60 grams (approximately 60 mL) of concentrated cannabis oil over a period of roughly 90 days. He described this as a cancer treatment protocol, though he also recommended it for numerous other conditions. The following is a detailed breakdown of the protocol as Simpson described it .

Goal

Consume 60 grams of concentrated, high-THC cannabis oil over approximately 90 days. Simpson considered this the minimum amount necessary for a serious cancer treatment course.

Titration schedule

• Week 1: Begin with a dose approximately the size of half a grain of dry rice—roughly 10 to 15 milligrams of oil—taken three times per day (morning, afternoon, and before bed). Total daily intake during this phase: approximately 30 to 45 milligrams. Simpson emphasized that the initial doses should be very small to allow the body to begin adjusting to the psychoactive effects of THC.

• Weeks 2 through 5: Double the dose approximately every four days. The purpose of the slow ramp-up was to build THC tolerance gradually and minimize disruption from the psychoactive effects. By the end of this escalation period—roughly four to five weeks in—the target was to reach approximately 1 gram (1,000 milligrams) of oil per day, divided into three roughly equal doses.

• Weeks 5 through 12: Maintain the full dose of approximately 1 gram per day, divided into three doses of roughly 333 milligrams each, and continue until the full 60 grams have been consumed. At this dosing level, the remaining 50-plus grams of oil would be consumed over the final seven to eight weeks.

Administration methods

• Primary method—oral: Simpson recommended placing the dose directly under the tongue (sublingual) or swallowing it. He considered oral ingestion the most important route for systemic absorption and the primary method for internal cancers and other systemic conditions.
• Secondary method—topical: For skin cancers and external lesions, Simpson recommended applying the oil directly to the affected area, covering it with a bandage, and changing the bandage every three to four days. He combined topical application with oral dosing for skin cancers.
• Not recommended as primary—inhalation: Simpson did not recommend smoking or vaporizing the oil as a primary treatment method. He acknowledged inhalation for immediate symptom relief (pain, nausea) but maintained that the oral route was necessary for the sustained, high-dose exposure he considered therapeutically essential.

Tolerance and the psychoactive effects

• Simpson maintained that patients would develop significant tolerance to the psychoactive effects of THC within approximately three to four weeks of consistent dosing at escalating levels.
• He considered the euphoric, sedating, or disorienting effects a minor and temporary side effect and strongly urged patients not to let the high discourage them from continuing the protocol.
• He recommended that patients take their initial doses at night or before bed to sleep through the most intense psychoactive effects during the early titration phase.
• Simpson also recommended that patients avoid driving or operating machinery during the titration period and that they inform family members about what to expect.

Post-protocol maintenance

• After completing the full 60-gram course, Simpson recommended a maintenance dose of approximately 1 to 2 grams of oil per month, taken indefinitely.
• He considered this ongoing low-dose maintenance important for long-term health and cancer prevention.
• Simpson indicated that maintenance dosing was much lower than the treatment dose and that patients who had completed the full protocol would have sufficient THC tolerance to handle it comfortably.

Dietary and lifestyle recommendations

• Simpson also advocated for dietary changes alongside the oil protocol, including reducing sugar intake, avoiding processed foods, and improving overall nutrition.
• He was not specific or systematic about dietary protocols compared to his highly detailed oil protocol—dietary advice was secondary and general.

Important context for evaluating this protocol

This protocol was designed by one person based on his personal experience and anecdotal observations. It was not developed through clinical trials, dose-finding studies, pharmacokinetic modeling, or any formal research process. Several critical points apply:

• No controlled trial validation. There are no published randomized controlled trials, cohort studies, or even well-documented case series evaluating this specific 60-gram/90-day protocol for any cancer type or any other condition.
• Assumes crude, unstandardized material. The 60-gram quantity assumes a single-strain, THC-dominant extract with no standardized potency. Actual THC content per gram of traditional RSO varied widely depending on the starting plant material and extraction technique.
• Very high THC exposure. At the peak dosing phase, patients were consuming roughly 1 gram of high-THC oil per day. Assuming traditional RSO contained 60 to 90 percent THC, this translates to approximately 600 to 900 milligrams of delta-9 THC per day—a dose far exceeding anything studied in controlled clinical settings. For context, the FDA-approved synthetic THC drug dronabinol is typically dosed at 2.5 to 20 milligrams per day.
• Real risks at these doses. Consuming 600 to 900 milligrams of THC daily carries serious risks including severe intoxication, impairment, anxiety, panic, tachycardia, hypotension, and cannabis use disorder. These risks are well-documented in the research [1][13][14][15].
• Oncology context. Patients with active cancer are often medically complex. Using unregulated, unstandardized cannabis oil as a primary cancer treatment—potentially in place of proven therapies—introduces harm that extends beyond the oil itself.

What is traditional Rick Simpson Oil—the product

Traditional RSO refers to the specific type of concentrated cannabis oil that Simpson made and advocated for. It was defined not by lab specifications or regulatory standards but by his method and materials. The following describes the product as Simpson produced it .

Source material

Simpson used high-THC, indica-dominant cannabis strains. He specifically favored heavy, sedating indica genetics and generally recommended against sativa-dominant strains for cancer treatment, believing that indica strains produced better therapeutic outcomes. He grew his own cannabis or sourced it from growers he trusted. There was no strain standardization—the starting material varied by availability and growing season.

Extraction solvent

Simpson originally used naphtha—a petroleum-based solvent commercially available as lighter fluid, Varsol, or similar products. He later also endorsed 99 percent isopropyl alcohol as an acceptable alternative. He explicitly warned against using other solvents, including butane or acetone, due to safety and purity concerns. Neither naphtha nor isopropyl alcohol is a food-grade solvent, which is a significant safety issue.

Extraction process

1. Dry or semi-dry cannabis plant material was placed in a container (typically a bucket).
2. The material was covered with solvent and agitated or stirred for several minutes to dissolve cannabinoids and other fat-soluble compounds from the plant.
3. The solvent was poured off through a filter, typically cheesecloth or a similar mesh material, into a separate collection vessel.
4. The process was repeated a second time with fresh solvent on the same plant material to extract remaining cannabinoids.
5. The combined solvent washes—now a dark, cannabinoid-rich liquid—were placed in a rice cooker or similar open-vessel heating device.
6. The solvent was evaporated at relatively low heat. Simpson recommended a rice cooker specifically because it maintains a temperature range that evaporates the solvent without exceeding the point at which cannabinoids degrade significantly. However, this temperature was still high enough to decarboxylate THCa into THC and to destroy most volatile terpenes.
7. As the solvent evaporated, a thick, dark oil remained at the bottom of the vessel.
8. The final oil was transferred into oral syringes for storage and dosing.

Appearance and physical characteristics

Traditional RSO was an extremely dark—nearly black—thick, viscous, tar-like oil. It had a strong cannabis odor and could carry a faint solvent-residual smell depending on how thoroughly the solvent was purged. The consistency was sticky and difficult to handle at room temperature but became more fluid when warmed slightly.

Cannabinoid profile

• Primarily decarboxylated delta-9 THC. The heat involved in solvent evaporation converted essentially all THCa in the extract into delta-9 THC. Traditional RSO was therefore an activated, THC-dominant product.
• Naturally occurring minor cannabinoids. Whatever CBD, CBN, CBC, CBG, and other minor cannabinoids the source strain contained were present at their natural ratios, but these were not controlled, measured, or targeted.
• No ratio control. There was no ability to adjust or standardize specific cannabinoid ratios. The profile was entirely determined by the genetics and growing conditions of the source plant.
• Estimated THC content. Depending on starting material, traditional RSO likely ranged from approximately 60 to 90 percent total THC by weight, though this was never lab-verified in the traditional production context.

Terpene content

Minimal to none. The combination of solvent extraction (which dissolves terpenes into the solvent along with cannabinoids) and the subsequent high-heat evaporation process (which volatilizes terpenes at temperatures well below cannabinoid degradation thresholds) meant that traditional RSO was effectively stripped of its terpene content.

Standardization and testing

None. Every batch of traditional RSO was different because it depended entirely on the starting plant material, growing conditions, solvent purity, extraction technique, evaporation temperature and duration, and the individual maker’s process. Simpson operated before cannabis legalization and the standardized lab-testing infrastructure that came with it. There was no Certificate of Analysis, no cannabinoid quantification, and no contaminant screening.

Residual solvent risk

This is one of the most significant safety concerns with traditional RSO production. Naphtha and isopropyl alcohol are not food-grade solvents. Naphtha in particular is a complex petroleum hydrocarbon mixture that may contain benzene, toluene, xylene, and other compounds with established toxicity. Incomplete solvent purging—which is very difficult to verify without analytical chemistry equipment—leaves potentially harmful residues in the finished oil. Modern extraction methods use food-grade ethanol or supercritical CO₂ specifically to address this problem.

Simpson’s claims vs. the evidence record

Rick Simpson made expansive therapeutic claims about his oil. He stated that RSO could cure cancer—including terminal cases—and that it was effective against diabetes, chronic pain, infections, glaucoma, arthritis, depression, insomnia, multiple sclerosis, and numerous other conditions. He was adamant, consistent, and public about these claims throughout his advocacy career .

It is important to evaluate these claims against the actual evidence base, using the same standards applied throughout this document.

What Simpson was not

Simpson was not a scientist, physician, pharmacologist, or researcher. He had no formal training in medicine, oncology, pharmacology, or clinical research methodology. He never designed, conducted, funded, or published a clinical trial. He never submitted his results to peer review. His entire evidence base consisted of personal experience, self-reported patient outcomes, and testimonials gathered informally—with no controls, no independent verification, no imaging confirmation, no long-term follow-up, and no blinding.

What the preclinical literature shows

The preclinical cannabinoid-cancer literature does exist, and it is scientifically interesting:

• In vitro studies have demonstrated that THC and CBD can induce apoptosis (programmed cell death), inhibit proliferation, and reduce angiogenesis (blood vessel formation that feeds tumors) in certain cancer cell lines .
• Animal model studies have shown some tumor-growth inhibition in mice and rats treated with cannabinoids .
• These findings have generated legitimate scientific interest and ongoing research.

What the preclinical literature does not show

• These findings have not translated into proven human cancer cures. The gap between in vitro or animal results and human clinical outcomes is vast, well-documented across all of oncology research, and especially relevant here.
• No human clinical trial has demonstrated that RSO or any cannabis oil preparation cures cancer.
• Several small human trials of cannabinoids in cancer contexts (particularly glioblastoma) have been conducted, but they have been exploratory, small, and have not produced the kind of results that would support cancer-cure claims .

Institutional positions

• The U.S. National Cancer Institute (NCI) acknowledges that cannabinoids have been studied for potential anticancer effects in laboratory and animal models but does not endorse cannabis or cannabis oil as a cancer treatment .
• The U.S. Food and Drug Administration (FDA) has not approved any cannabis plant product for the treatment of cancer. The only FDA-approved cannabinoid-related products are for other specific indications: Epidiolex (CBD) for certain seizure disorders and dronabinol/nabilone (synthetic THC analogues) for chemotherapy-related nausea and AIDS-related wasting [1].
• Health Canada has never approved RSO or cannabis oil as a cancer cure.
• NCCIH explicitly states that the strongest cannabinoid evidence is for rare epilepsies, chemotherapy-related nausea and vomiting, and appetite-related indications in HIV/AIDS—not cancer cure [1].

What Simpson got right

Simpson drew attention to cannabinoids as a serious area of biomedical research at a time when most of the world was ignoring or actively suppressing that conversation. His advocacy—however scientifically imprecise—helped create the political, cultural, and social conditions for the legal cannabis industry and the cannabinoid research infrastructure that exists today. He was among the first to bring concentrated cannabis oil to widespread public awareness, and the term RSO itself remains the most recognized name for full-spectrum cannabis extract in the consumer vocabulary. These contributions are real and historically significant.

What he overstated

The leap from preclinical signals to cancer cure was not supported by human evidence when Simpson made it, and it is not supported now. Encouraging patients—particularly cancer patients—to rely on RSO as a primary treatment in place of proven oncologic therapies (surgery, radiation, chemotherapy, immunotherapy) carries genuine harm potential. Delayed or foregone treatment for treatable cancers is a documented concern in the alternative-medicine literature. Simpson’s absolute certainty about curative claims, while understandable from a personal-experience perspective, exceeded what the evidence could support and still exceeds it today.

WHAT MAKES OUR RSO DIFFERENT—THE OILWELL APPROACH

The origin of OilWell Cannabis

We are OilWell Cannabis, founded in Houston, Texas, by Colin Valencia. Colin grew up in McAllen, Texas—right across the river from Reynosa, Tamaulipas, Mexico. The McAllen-Reynosa area, known as the Borderplex, is one of the most economically challenged and dangerous regions along the U.S.-Mexico border. McAllen is a city of contrasts—vibrant culture and a thriving retail sector, yet deeply affected by poverty and limited opportunities outside of the retail and healthcare industries. Reynosa, on the other hand, is an industrial hub plagued by violence and cartel activity.

Colin’s childhood in McAllen meant learning to hustle early, taking on risky work in transporting items across the border. Those early experiences exposed him to complexities and dangers. A lot of his best friends have been killed or are in prison because of the associated dangers. By sixteen, one way or another, he had to leave home for good.

Despite the dangers, Colin did not fall into the darkest paths—like selling harder substances. Instead, he focused on cannabis, seeing it as a safer and more beneficial alternative. He grew up in the traditional cannabis world long before legalization, learning the plant intimately while operating in the shadows. Over time, he transitioned from those early, risky ventures to creating a legal, legitimate business.

Colin later became a formally trained software engineer and did custom development work for Baylor College of Medicine, one of the most prestigious medical institutions in the Texas Medical Center. That combination—deep cannabis plant knowledge plus medical-grade technical precision—defines how we approach every formula we create.

Bentley’s story—our true beginning

We didn’t start with a business plan. We started with a dog named Bentley.

Bentley was more than just a pet; he was family, a companion who stood by Colin through the toughest times. When Bentley fell seriously ill, veterinarians delivered the verdict no pet owner wants to hear: euthanasia was the only humane option. Bentley was paralyzed in his back legs. They said the pain medications would destroy his internal organs, causing him more pain and suffering. The choice was painful prolonged decline or immediate mercy killing.

But giving up on Bentley was not an option. In a desperate search for alternatives, Colin stumbled upon the healing properties of CBD. A kind-hearted rescue worker named Jessica asked: “You’ve moved how many tons of weed and you’ve never heard of CBD?”

That question exposed a blind spot that became our mission. Colin learned to create CBD golden paste—a specialized cannabinoid formula for pets. It was not a cure, but it was a lifeline. And that hope delivered something veterinary medicine said was impossible: Bentley got up. He walked over to Colin and brought him his ball to play. From paralyzed to fetching—this was not placebo; dogs do not respond to placebo. This was cannabinoid medicine doing what pharmaceuticals could not.

Bentley lived another ten years, passing naturally at age twenty. During those ten years, Colin developed specialized cannabis formulas for every age-related condition Bentley faced. Neurodegeneration led to understanding CBG’s neuroprotective properties and THCa’s PPARγ agonism for brain cell protection. Dementia led to CBC’s role in neurogenesis. Glaucoma led to THC’s CB1 agonism for intraocular pressure reduction. Crippling arthritis led to multi-pathway anti-inflammatory approaches using CBD, CBG, THCa, and beta-caryophyllene working through different receptor systems simultaneously.

Single cannabinoids were not enough. Bentley’s evolving conditions required multi-cannabinoid synergy. Minor cannabinoids became critical. Precision mattered—Bentley’s life depended on it.

Our own fight—Colin’s PTSD and benzo withdrawal

Colin also knows pharmaceutical dependence personally. He struggled with PTSD and benzodiazepine addiction. When he decided to break free from Xanax, he did it cold turkey—a feat notoriously difficult and dangerous—using the cannabinoid knowledge developed keeping Bentley alive. Our Peace Gummies formula was created during midnight experiments while fighting through benzo withdrawal. Colin personally uses the vape form for insomnia and severe PTSD. This is not theoretical knowledge; he lived what RSO patients live.

Building for people, not just profit

Over time, the therapeutic benefits of cannabis became the core of our work. We’ve developed formulas that doctors use for Crohn’s disease, IBS, ulcerative colitis, PTSD, benzo addiction, and insomnia. Our focus has always been making cannabis accessible and effective for everyone—vegans, diabetics, and those with specific health needs.

Why we publish our formulas—open-source from day one

We publish our complete RSO formulas publicly—every cannabinoid, every milligram amount, every percentage—so that anyone who cannot afford our products can source the ingredients and make their own version. This is a direct echo of Rick Simpson’s original ethos. Simpson gave his oil away for free and taught people how to make it. We adapt that for the modern marketplace: we sell a professionally manufactured, lab-tested, standardized product for those who want it, and we publish the complete recipe for those who want to make it themselves.

As Colin said on ABC13 in 2019: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

The open-source philosophy started with Bentley. On our About Us page, we published the actual CBD golden paste recipe that saved Bentley’s life, so any pet owner facing a similar crisis could make it themselves:

CBD golden paste recipe for pets—the original open-source formula

Ingredients:

• 1/2 cup organic turmeric powder
• 1 cup water
• 1/3 cup coconut oil (unrefined, organic)
• 1 to 2 teaspoons freshly ground black pepper (important for absorption)
• CBD oil (dosage depends on the size and needs of the pet; consult with a veterinarian)

Instructions:

1. Mix the turmeric and water in a saucepan over low heat, stirring continuously until a thick paste forms (about 7 to 10 minutes). Add a little more water if it becomes too thick.
2. Add the coconut oil and freshly ground black pepper. Stir until all ingredients are thoroughly mixed.
3. Allow the paste to cool, then transfer it to a jar with a lid. Store it in the refrigerator for up to two weeks.
4. Add a small amount of CBD oil to the paste before giving it to the pet, adjusting the dosage based on their weight and health needs. Start low and gradually increase as needed.

Serving suggestion: Mix a small amount of the golden paste with the pet’s food once or twice a day. Monitor the pet for any changes and consult with a veterinarian if there are any concerns. Always consult a veterinarian before starting any new supplement regimen for a pet.

This recipe—published for free, years before the RSO formulas—demonstrates that the pattern is consistent. We gave away the formula that saved Bentley before we gave away the formula designed for people. The open-source ethos is not a marketing strategy; it’s the foundational behavior of our company.

FARM BILL COMPLIANCE—LEGAL CANNABIS ACCESS FOR NEW MEXICO

Our products are legal under the 2018 Farm Bill because they contain less than 0.3 percent delta-9 THC by dry weight at the point of sale. Our RSO Sublingual Oil contains only 90 milligrams of delta-9 THC in the entire 30 mL bottle—all hemp-derived, all compliant.

THCa is the acidic, non-psychoactive precursor to delta-9 THC. It is Farm Bill compliant at the point of sale because it has not been converted to delta-9 THC. The practical significance is huge: you can legally purchase, possess, and transport our product, then activate it at home.

Home decarboxylation converts 1,500 mg THCa → ~1,315 mg delta-9 THC. Combined with the existing 90 mg delta-9 THC, this yields ~1,405 mg total delta-9 THC—giving you psychoactive potency comparable to traditional illegal RSO, entirely at your discretion after purchase. The conversion chemistry: THCa has a molecular weight of 358.47 g/mol; the conversion ratio is approximately 1 mg THCa = 0.877 mg delta-9 THC after decarboxylation.

Important legal notice: THCa converts to delta-9 THC when heated. Customers are responsible for understanding and complying with New Mexico laws regarding cannabinoid products. We ship with full documentation, Certificates of Analysis, and receipts. International customers accept all customs and legal responsibility.

New Mexico legalized recreational cannabis in 2022 and operates a regulated adult-use and medical cannabis program. Our Farm Bill-compliant products can be shipped to any address in New Mexico legally. If you hold a New Mexico medical cannabis card, you can still purchase our products without needing to use your card—no qualifying condition required.

THE DECARBOXYLATION CHOICE—YOU CONTROL THE POTENCY

Traditional RSO was always fully decarboxylated. The heat of solvent evaporation converted all THCa into delta-9 THC, leaving no choice about psychoactivity.

Our sublingual formula contains 1,500 mg THCa in its acidic, non-psychoactive form. This creates three distinct usage options:

Option 1—Raw, no heat. All 1,500 mg stays as THCa—completely non-psychoactive. The THCa evidence profile suggests potential anti-inflammatory activity via COX-2 inhibition and neuroprotective potential via PPARγ agonism [12]. This option is compatible with work, driving, and daytime use with zero psychoactive impairment.

Option 2—Fully activated, home decarboxylation. Heat the oil at 260°F (125°C) for 45 to 60 minutes in an oven-safe glass container. This yields ~1,405 mg total delta-9 THC. You may also transfer a controlled portion of the oil into a second oven-safe container, decarboxylating only what you intend to use and preserving the remainder in its raw THCa form.

Option 3—Vape, auto-decarboxylation. Our RSO Vape Cartridge vaporizes at 400 to 450°F, instantly converting THCa to delta-9 THC with each inhalation. Every puff delivers freshly decarboxylated cannabinoids. This is the fastest-onset RSO delivery method available.

SOLVENT-FREE PRODUCTION—SAFETY FIRST

Our RSO is not an extraction product in the traditional sense. It is a formulated blend of individual cannabinoid distillates and isolates combined at specific ratios in a controlled production environment. No naphtha. No isopropyl alcohol. No butane. No extraction solvents are present in the finished product.

We use organic MCT oil (medium-chain triglycerides) as the carrier base. MCT oil is a food-grade lipid carrier that facilitates cannabinoid absorption through sublingual tissue and provides a neutral taste profile.

Third-party lab testing covers cannabinoid potency, terpene profile, and safety panels including pesticides, heavy metals, residual solvents, and microbial contaminants. Certificates of Analysis (COAs) are available on request and accessible through our website.

TWO PRODUCT FORMATS—CHOOSE YOUR DELIVERY

We offer the RSO formula in two delivery formats, each designed for different use cases and pharmacokinetic profiles.

RSO Sublingual Oil—$129.99

• 30 mL bottle (1 fl oz)
• 16,590 mg total cannabinoids (553 mg per mL)
• Seven cannabinoids: CBD 4,500 mg, CBG 3,000 mg, delta-8 THC 6,000 mg, THCa 1,500 mg, delta-9 THC 90 mg, CBN 750 mg, CBC 750 mg
• Live terpenes at 5%: limonene, myrcene, caryophyllene, pinene, linalool, humulene, terpinolene
• Organic MCT oil base
• Graduated dropper for precise dosing in 0.1 mL increments
• Onset: 15 to 45 minutes (sublingual absorption)
• Peak effects: 1 to 2 hours
• Duration: 4 to 6 hours
• Bioavailability: 13 to 19 percent
• Approximately 40 to 60 doses per bottle depending on serving size

RSO Vape Cartridge—$49.99

• 1-gram cartridge
• 900 mg+ total cannabinoids
• Same six-cannabinoid ratio as sublingual formula
• Live terpenes at 5%+
• 510-thread universal battery compatibility
• Onset: 1 to 2 minutes (fastest cannabinoid delivery)
• Peak effects: 10 to 15 minutes
• Duration: 2 to 4 hours
• Bioavailability: 10 to 35 percent
• Automatic THCa decarboxylation at vaping temperature (400 to 450°F)

When to use each format

Use case	Recommended format	Rationale
Fast relief (acute pain, nausea, panic)	Vape	1-2 minute onset
Sustained relief (chronic pain, sleep)	Sublingual	4-6 hour duration
Maximum bioavailability	Sublingual	13-19% absorption
Portability and discretion	Vape	Compact, no measuring
Precise dosing control	Sublingual	Graduated dropper
Daytime non-psychoactive use	Sublingual (raw)	THCa stays inactive
Nighttime psychoactive use	Sublingual (decarbed) or Vape	Activated THCa + delta-8 THC

COMPETITIVE COMPARISON—WHAT SETS US APART

We don’t name competitors, but we want you to understand the differences you’ll find when shopping for RSO in New Mexico.

Traditional RSO (historic model):

• Single high-THC strain, no standardization
• Solvent-based extraction (naphtha or isopropyl alcohol)
• No terpenes (destroyed by heat)
• Unknown potency per batch
• No lab testing or COA
• High delta-9 THC (600–900 mg/day at peak Simpson dosing)
• No format options

Other “RSO” products on the market:

• Some contain only THC, missing other cannabinoids
• Others are hemp-derived CBD RSO with ~1,000 mg total cannabinoids vs. our 16,590 mg
• Many lack patient-controlled potency—always psychoactive
• Require medical cards or have access restrictions
• May not ship to New Mexico or have limited delivery

OilWell RSO:

• Seven defined cannabinoids at precise ratios
• Live terpenes at 5%
• Solvent-free, MCT oil base
• Full third-party lab testing (potency, terpenes, pesticides, heavy metals, residual solvents, microbial)
• 90 mg total delta-9 THC (well under 0.3% Farm Bill limit)
• 1,500 mg THCa—customer controls decarboxylation
• Two formats: sublingual oil and vape cartridge
• Ships nationwide to New Mexico, no medical card required

CONDITION-SPECIFIC USAGE CONTEXT—FOR NEW MEXICO PATIENTS

Important disclaimer: The following usage contexts are informed by cannabinoid research and our formulation rationale. They are not medical prescriptions, not FDA-approved treatment protocols, and not a substitute for professional medical care. These products have not been evaluated by the Food and Drug Administration and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare provider before using cannabinoid products, especially if you have a medical condition, are taking medications, are pregnant or nursing, or have any health concerns. Do not operate vehicles or machinery while under the influence of psychoactive cannabinoids.

If you are a New Mexico resident dealing with cancer, chronic pain, sleep disorders, or PTSD, please also consult local specialists—oncologists at the University of New Mexico Comprehensive Cancer Center, pain management clinics in Albuquerque, or veteran support services through the New Mexico VA system—to integrate cannabinoid use into a comprehensive care plan.

Chemotherapy-related nausea and appetite support (for New Mexico cancer patients):

• Pre-chemo: 0.5 to 1.0 mL sublingual approximately 1 hour before treatment
• Acute breakthrough nausea: 2 to 3 vape puffs for immediate relief (1-2 minute onset)
• Post-chemo: 0.5 mL sublingual every 6 hours as needed
• Sleep support during treatment: 1.0 to 2.0 mL sublingual before bed (delivers 25 to 50 mg CBN)

Chronic pain (fibromyalgia, arthritis, neuropathy) common in New Mexico’s aging and veteran populations:

• Daytime: 0.3 to 0.5 mL raw sublingual—provides anti-inflammatory cannabinoid exposure without psychoactive impairment
• Nighttime: 0.5 to 1.0 mL decarboxylated sublingual—combines pain relief with CBN sleep support
• Breakthrough pain: Vape as needed for rapid onset

Sleep support (for New Mexico’s high rates of insomnia):

• Before bed: 1.0 to 2.0 mL sublingual
• At 2.0 mL, this delivers 50 mg CBN—the dosage level investigated in 2024 sleep literature
• At 1.0 mL, this delivers 25 mg CBN—above the 20 mg threshold associated with reduced sleep disturbance

Anxiety and stress (especially relevant for New Mexico’s frontline workers and military community):

• Daytime functional relief: 0.3 mL raw sublingual—CBD and CBG address anxiety pathways without impairment
• Nighttime: 1.0 mL sublingual—full cannabinoid profile including CBN for sleep architecture

General titration principle: Start low, go slow. Begin with 0.25 to 0.5 mL sublingual and assess effects over 2 to 3 hours before increasing. Individual responses vary based on body weight, metabolism, tolerance, concurrent medications, and other factors.

DELIVERY TO NEW MEXICO—FAST, LEGAL, DISCREET

We are the only company offering nationwide RSO delivery with the transparency New Mexico residents deserve.

Shipping to New Mexico:

• All orders ship via USPS Priority Mail (2–3 business days), FedEx, or UPS Ground (3–5 business days)
• Discreet packaging—no cannabis branding visible
• Tracking provided for all orders
• Temperature-stable packaging for summer shipments
• Signature-required option available

Same-day delivery? Currently available only in Houston’s Texas Medical Center and surrounding zones. For New Mexico, we rely on fast nationwide shipping. Orders placed before 2 PM Central time typically ship same day.

International shipping: We ship globally. The THCa legal framework makes this possible—our product contains <0.3% delta-9 THC at point of sale. International customers receive full documentation, COAs, and receipts for customs.

New Mexico address? Just enter your shipping address at checkout—Albuquerque, Santa Fe, Las Cruces, Farmington, Roswell, Hobbs, Clovis, or any rural route. We’ll get it to you.

Contact: Call us at (832) 416-2816 or email [email protected] with any questions about shipping to New Mexico.

ABC13 HOUSTON MEDIA RECOGNITION—SEVEN FEATURES, FOUR YEARS

ABC13 (KTRK) Houston, the ABC affiliate in America’s fourth-largest city, featured Colin Valencia and OilWell Cannabis in seven distinct news segments from 2019 to 2023. Five different reporters sought us out: Tom Abrahams, Steve Campion, Shelley Childers, Nick Natario, and KTRK staff. No other Houston cannabis operator appears with that frequency or across that breadth of topics.

Feature 1 (Sept. 15, 2019): Texas CBD businesses booming as industry continues to evolve. This is where Colin’s foundational quote aired: “I’m not trying to sell people snake oil. I’m not trying to sell people hope, but there’s enough research out there that people just need to know and try and have the best possible version to base their opinions off of to give it a fair shot as to whether it’s right or wrong for them.”

Feature 2 (Mar. 22, 2021): Entrepreneur creates direct-to-consumer business ahead of marijuana decriminalization efforts. Colin’s therapy quote: “Pain comes in a lot of different forms.”

Feature 3 (May 24, 2021): What is Delta 8 THC and why is it considered legal weed in Texas. Steve Campion’s blunt exchange: “Maybe you want to get high.”

Feature 4 (Aug. 20, 2021): Houston CBD shop giving away free products to those who get COVID vaccine. We gave away 1,000 caviar pre-rolls (~$35,000 in product) to encourage vaccination, coordinated with the city of Houston.

Feature 5 (Oct. 19, 2021): Texas ban over once legal hemp product, Delta 8, raises questions over legality. We proactively removed all Delta-8 products before enforcement and warned other operators.

Feature 6 (Oct. 7, 2022): Biden marijuana pardon—experts weigh in on why Texas won’t see impact. Colin revealed his personal marijuana conviction history: “I would love to see people not get hurt for this anymore.”

Feature 7 (Apr. 21, 2023): Marijuana industry getting creative as Texas laws continue to change. Colin’s “Renaissance” framing: “Right now is actually a pretty—like Renaissance—pretty important time that should be enjoyed now.”

All 13 quotes indexed chronologically—from the first snake-oil quote (2019) to the Renaissance quote (2023)—show consistency, honesty, and evolution. These features cannot be purchased; they are earned editorial recognition.

GENERAL KNOWLEDGE—EVIDENCE FOR EVERY COMPOUND

Research method and evidence weighting

We prioritize sources in this order: human clinical evidence, systematic reviews and meta-analyses, NIH and other institutional summaries, then mechanistic or preclinical literature when human data are sparse. That weighting matters here because the evidence base is not evenly distributed. Of the compounds in our formula, CBD and delta-9 THC have the strongest human literature; delta-8 THC, THCa, CBG, CBN, CBC, and most terpenes are still much more dependent on reviews, animal work, in vitro pharmacology, or early translational literature [1]-[29].

Institutional baseline from NIH and related sources

• NCCIH states that the strongest established cannabinoid evidence is for certain rare epilepsies, chemotherapy-related nausea and vomiting, and appetite or weight-loss indications associated with HIV/AIDS. It also notes only modest evidence for chronic pain and multiple-sclerosis-related symptoms, with many other claimed uses still in early-stage research [1].
• NCCIH emphasizes that the FDA has not approved the cannabis plant itself for medical use, although purified CBD and synthetic THC-like drugs have specific approvals [1].
• Safety concerns repeatedly highlighted by NIH include impairment, motor vehicle crash risk, cannabis use disorder, pregnancy-related concerns, accidental pediatric exposure, contamination or labeling inaccuracy, and THC-vape lung-injury concerns [1].
• NCCIH warns that over-the-counter CBD products may differ from their labels and that CBD itself has been associated with decreased alertness, gastrointestinal effects, liver-related adverse effects, and drug interactions [1].

Cannabinoid evidence profiles

CBD:

• Strongest human evidence in seizure disorders [1][2].
• 2024 meta-analysis shows anxiolytic signal but limited clinical sample [3].
• 2024 pain review: promising but heterogeneous, trial quality limiting [4].
• 2023 insomnia review: methodologically weak, few objective assessments [5].
• 2023 meta-analysis shows liver enzyme elevation and possible drug-induced liver injury, especially relevant for concentrated oral products [6].

CBG:

• Mostly review and preclinical; human evidence sparse [7][8].
• Mechanistically interesting but commercially sold while evidence base remains thin [7].

Delta-8 THC:

• Pharmacologically relevant, psychoactive, less clinically characterized than delta-9 THC [9]-[11].
• 2022 review: similar PK/PD to delta-9, weaker CB1 affinity, less potent [9].
• 2023 scoping review: dominated by animal studies, product chemistry, use reports, regulatory concerns [10].
• Manufacturing concerns: greater stability, easier synthesis, product-byproduct questions [11].

THCa:

• Acidic precursor of THC; may represent large share of raw plant material.
• Does not produce psychoactive effects if stays acidic, but decarboxylates during heating or storage [12].
• In vitro and rodent literature suggest anti-inflammatory, immunomodulatory, neuroprotective, antineoplastic possibilities—not equivalent to human outcomes [12].

Delta-9 THC:

• Strongest human evidence among psychoactive cannabinoids, clearest adverse-effect burden [1][13]-[15].
• NCCIH: relevant to chemo nausea, HIV appetite, some MS/pain outcomes [1].
• 2022 pain review: high-THC products may provide short-term benefit but increase dizziness, sedation, nausea, discontinuation [13].
• Pharmacokinetics: inhaled onset seconds-minutes, peaks 15-30 min; oral onset later, peak later, longer duration [14].
• 2025 review: high-concentration THC products unfavorably associated with psychosis/schizophrenia, CUD, anxiety, depression [15].

CBN:

• Weak human evidence; marketing ahead of data [12][16][17].
• 2021 review screened 99 abstracts, found no clinical trials with validated sleep measures [16].
• 2024 sleep review: still mismatched to real-world use, need better trials [17].

CBC:

• Emerging, intriguing, overwhelmingly preclinical [18][19].
• 2024 review: distinct PK/PD, antinociceptive, antibacterial, anti-seizure targets [18].
• Over-the-counter CBC products sold despite little efficacy/safety evidence [18].

Terpene evidence profiles

Limonene:

• Review/preclinical; antioxidant, anti-inflammatory, cardioprotective, gastroprotective, immune-modulatory [20][21].
• Oxidation products (hydroperoxides) are contact allergens [22].

Myrcene:

• Mostly preclinical; human evidence lacking [20][23].
• Often marketed as sedative—stronger claim than evidence supports [23].

Caryophyllene (β-caryophyllene):

• Selective CB2 agonist—mechanistically interesting [24].
• Anti-inflammatory, immunomodulatory, antioxidant, neuroprotective, gastroprotective [24].

Pinene:

• Promising preclinical, weak human confirmation [20][25].
• Brain-health review: antioxidant, anti-inflammatory, neuroprotective signals warrant study [25].

Linalool:

• Substantial preclinical, limited direct clinical confirmation [20][22][25][26].
• Oxidized linalool hydroperoxides are allergens [22].

Humulene:

• Translationally interesting, early stage [20][27].
• 2024 scoping review: anti-inflammatory, cannabimimetic properties via CB1 and adenosine A2a pathways [27].

Terpinolene:

• Least clinically characterized [20][28].
• 2021 review: biological effects reported but evidence base dominated by in silico, in vitro, animal studies [28].

Research limits and interpretation

• Evidence base is highly uneven; CBD and delta-9 THC support most detailed statements; others require caution [1]-[29].
• Whole-cannabis extract, purified molecule, semisynthetic, and terpene-only data are not interchangeable.
• Minor cannabinoids and terpenes are commercially interesting because underexplored—claims often inflated.
• Product quality matters as much as molecule identity: labeling inaccuracies, contamination, synthesis byproducts, dose variability, route-dependent PK all affect real-world interpretation [1][10][11][14].
• THCa chemistry changes with storage/heating; acidic cannabinoids convert to neutral forms [12].

Common overstatements to avoid

• Overstatement: CBN is a clinically proven sleep cannabinoid.
  More accurate: specific sleep evidence for CBN remains weak, no strong validated-trial base [16][17].

• Overstatement: Myrcene is a proven human sedative explaining couch-lock.
  More accurate: plausible preclinical bioactivity, but direct human proof limited [23].

• Overstatement: Terpenes have proven entourage effects in patients.
  More accurate: entourage hypotheses influential, but robust clinical proof limited and compound-specific [20][29].

• Overstatement: THCa is always nonpsychoactive.
  More accurate: THCa itself not psychoactive, but heating/processing converts to THC [12].

• Overstatement: Delta-8 THC is safe because hemp-derived.
  More accurate: psychoactive, pharmacologically close to delta-9, entangled with manufacturing/testing concerns [9]-[11].

Practical takeaways for our formulas

• Most evidence-developed actives: CBD and delta-9 THC.
• Delta-8 THC not trivial—psychoactive cannabinoid with less robust safety/efficacy characterization.
• THCa meaningfully changes with processing—interpret differently raw vs. heated.
• CBG, CBN, CBC scientifically credible but clinically immature.
• Terpenes relevant to aroma/flavor, possibly biologic activity, but compound-specific therapeutic claims should be conservative.

RSO SUBLINGUAL OIL—THE OPEN-SOURCE FORMULA

Cannabinoid	Amount
CBD	4,500 mg
CBG	3,000 mg
Delta-8 THC	6,000 mg
THCa	1,500 mg
Delta-9 THC	90 mg
CBN	750 mg
CBC	750 mg
Total Cannabinoids	16,590 mg

• Live Terpenes: 5%
• Format: 30 mL bottle
• Active cannabinoids per mL: 553 mg

Price: $129.99
Order: OilWell RSO Sublingual Oil

RSO VAPE CARTRIDGE—INSTANT RELIEF

Cannabinoid	Percentage
CBD	30%
CBG	20%
Delta-8 THC	15%
THCa	10%
CBN	10%
CBC	10%

• Live Terpenes: 5%
• Format: 1 Gram cartridge
• Compatible with 510-thread batteries

Price: $49.99
Order: OilWell RSO Vape Cartridge

TERPENE PROFILE—BOTH PRODUCTS

• Limonene (citrus-bright)
• Myrcene
• Caryophyllene (β-caryophyllene—pepper/spice)
• Pinene (forest-fresh)
• Linalool (floral, lavender)
• Humulene (earthy, woody)
• Terpinolene (piney, fruity, sparkling)

These terpenes complement the cannabinoid formula: limonene for mood, myrcene for relaxation, caryophyllene for CB2 activation, pinene for clarity, linalool for calm, humulene for inflammation, terpinolene for complexity.

BRINGING IT HOME FOR NEW MEXICO

We know New Mexico. We know the high desert air, the sunsets over the Sandia Mountains, the tight-knit communities from Gallup to Alamogordo. We know that cancer touches families in every corner of the state, that veterans in Clovis and Las Cruces are looking for alternatives to pills, that chronic pain patients in Farmington deserve better than endless prescription cycles.

We built OilWell for people like you—people who need real information, not hype; people who want control over their medicine; people who value transparency and safety. Our open-source formulas mean you can see exactly what’s in every bottle. Our lab testing means you can trust what’s on the label. Our Farm Bill compliance means you can order legally from New Mexico without a medical card.

If you’re ready to try a multi-cannabinoid RSO that respects both science and your autonomy, place your order today. We’ll ship it discreetly to your door anywhere in New Mexico. If you can’t afford our product, use our published formula to make your own—just like Rick Simpson taught, but safer and more precise.

Order now: OilWell RSO Sublingual Oil | OilWell RSO Vape Cartridge

Questions? Call (832) 416-2816 or email [email protected].

Thank you for trusting us to be your guide. From Houston to Albuquerque, from Bentley’s story to your own—we’re here to help you find what works.

REFERENCES

Traditional RSO Section

RS1. Simpson R. Phoenix Tears: The Rick Simpson Story. Simpson RamaDur LLC; 2012.
RS2. Laurette C, director. Run From The Cure: The Rick Simpson Story . 2005. Distributed via phoenixtears.ca and online platforms.
RS3. Simpson R. Instructions and dosing information published on phoenixtears.ca. Multiple dates. Accessed March 2026.
RS4. Velasco G, Sánchez C, Guzmán M. Towards the use of cannabinoids as antitumour agents. Nat Rev Cancer. 2012;12(6):436-444. PMID: 22555283.
RS5. Guzmán M, Duarte MJ, Blázquez C, et al. A pilot clinical study of delta-9-tetrahydrocannabinol in patients with recurrent glioblastoma multiforme. Br J Cancer. 2006;95(2):197-203. PMID: 16804518.
RS6. National Cancer Institute. Cannabis and Cannabinoids (PDQ)—Health Professional Version. NIH/NCI. Updated 2024. Available at: https://www.cancer.gov/about-cancer/treatment/cam/hp/cannabis-pdq

General Knowledge Section

1. National Center for Complementary and Integrative Health. Cannabis Marijuana and Cannabinoids: What You Need To Know. NIH/NCCIH. Accessed March 2026. Available at: https://www.nccih.nih.gov/health/cannabis-marijuana-and-cannabinoids-what-you-need-to-know
2. Talwar A, Estes E, Aparasu R, Reddy DS. Clinical efficacy and safety of cannabidiol for pediatric refractory epilepsy indications: A systematic review and meta-analysis. Exp Neurol. 2023;359:114238. PMID: 36206805.
3. Han K, Wang JY, Wang PY, Peng YC. Therapeutic potential of cannabidiol CBD in anxiety disorders: A systematic review and meta-analysis. Psychiatry Res. 2024;339:116049. PMID: 38924898.
4. Cásedas G, Yarza-Sancho M, López V. Cannabidiol CBD: A systematic review of clinical and preclinical evidence in the treatment of pain. Pharmaceuticals Basel. 2024;17(11):1438. PMID: 39598350.
5. Ranum RM, Whipple MO, Croghan I, Bauer B, Toussaint LL, Vincent A. Use of cannabidiol in the management of insomnia: A systematic review. Cannabis Cannabinoid Res. 2023;8(2):213-229. PMID: 36149724.
6. Lo LA, Christiansen A, Eadie L, Strickland JC, Kim DD, Boivin M, Barr AM, MacCallum CA. Cannabidiol-associated hepatotoxicity: A systematic review and meta-analysis. J Intern Med. 2023;293(6):724-752. PMID: 36912195.
7. Nachnani R, Raup-Konsavage WM, Vrana KE. The pharmacological case for cannabigerol. J Pharmacol Exp Ther. 2021;376(2):204-212. PMID: 33168643.
8. Li S, Li W, Malhi NK, Huang J, Li Q, Zhou Z, Wang R, Peng J, Yin T, Wang H. Cannabigerol CBG: A comprehensive review of its molecular mechanisms and therapeutic potential. Molecules. 2024;29(22):5471. PMID: 39598860.
9. Tagen M, Klumpers LE. Review of delta-8-tetrahydrocannabinol delta8 THC: Comparative pharmacology with delta9 THC. Br J Pharmacol. 2022;179(15):3915-3933. PMID: 35523678.
10. LoParco CR, Rossheim ME, Walters ST, Zhou Z, Olsson S, Sussman SY. Delta-8 tetrahydrocannabinol: A scoping review and commentary. Addiction. 2023;118(6):1011-1028. PMID: 36710464.
11. Abdel-Kader MS, Radwan MM, Metwaly AM, Eissa IH, Hazekamp A, ElSohly MA. Chemistry and pharmacology of Delta-8-Tetrahydrocannabinol. Molecules. 2024;29(6):1249. PMID: 38542886.
12. Moreno-Sanz G. Can You Pass the Acid Test? Critical review and novel therapeutic perspectives of delta9-Tetrahydrocannabinolic Acid A. Cannabis Cannabinoid Res. 2016;1(1):124-130. PMID: 28861488.
13. McDonagh MS, Morasco BJ, Wagner J, Ahmed AY, Fu R, Kansagara D, Chou R. Cannabis-based products for chronic pain: A systematic review. Ann Intern Med. 2022;175(8):1143-1153. PMID: 35667066.
14. Grotenhermen F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin Pharmacokinet. 2003;42(4):327-360. PMID: 12648025.
15. Rittiphairoj T, Leslie L, Oberste JP, Yim TW, Tung G, Bero L, Riggs P, Hutchison K, Samet J, Li T. High-concentration delta-9-tetrahydrocannabinol cannabis products and mental health outcomes: A systematic review. Ann Intern Med. 2025;178(10):1429-1440. PMID: 40854216.
16. Corroon J. Cannabinol and sleep: Separating fact from fiction. Cannabis Cannabinoid Res. 2021;6(5):366-371. PMID: 34468204.
17. Lavender I, Garden G, Grunstein RR, Yee BJ, Hoyos CM. Using cannabis and CBD to sleep: An updated review. Curr Psychiatry Rep. 2024;26(12):712-727. PMID: 39612156.
18. Sepulveda DE, Vrana KE, Kellogg JJ, Bisanz JE, Desai D, Graziane NM, Raup-Konsavage WM. The potential of cannabichromene as a therapeutic agent. J Pharmacol Exp Ther. 2024;391(2):206-213. PMID: 38777605.
19. Zagožen M, Čerenak A, Kreft S. Cannabigerol and cannabichromene in Cannabis sativa L. Acta Pharm. 2021;71(3):355-364. PMID: 36654096.
20. André R, Gomes AP, Pereira-Leite C, Marques-da-Costa A, Monteiro Rodrigues L, Sassano M, Rijo P, Costa MDC. The entourage effect in cannabis medicinal products: A comprehensive review. Pharmaceuticals Basel. 2024;17(11):1543. PMID: 39598452.
21. Anandakumar P, Kamaraj S, Vanitha MK. D-limonene: A multifunctional compound with potent therapeutic effects. J Food Biochem. 2021;45(1):e13566. PMID: 33289132.
22. Ogueta IA, Brared Christensson J, Giménez-Arnau E, Brans R, Wilkinson M, Stingeni L, Foti C, Aerts O, Svedman C, Gonçalo M, Giménez-Arnau A. Limonene and linalool hydroperoxides review: Pros and cons for routine patch testing. Contact Dermatitis. 2022;87(1):1-12. PMID: 35122274.
23. Surendran S, Qassadi F, Surendran G, Lilley D, Heinrich M. Myrcene: What are the potential health benefits of this flavouring and aroma agent? Front Nutr. 2021;8:699666. PMID: 34350208.
24. Hashiesh HM, Sharma C, Goyal SN, Sadek B, Jha NK, Al Kaabi J, Ojha S. A focused review on CB2 receptor-selective pharmacological properties and therapeutic potential of beta-caryophyllene, a dietary cannabinoid. Biomed Pharmacother. 2021;140:111639. PMID: 34091179.
25. Weston-Green K, Clunas H, Jimenez Naranjo C. A review of the potential use of pinene and linalool as terpene-based medicines for brain health: Discovering novel therapeutics in the flavours and fragrances of cannabis. Front Psychiatry. 2021;12:583211. PMID: 34512404.
26. Dos Santos ÉRQ, Maia JGS, Fontes-Júnior EA, do Socorro Ferraz Maia C. Linalool as a therapeutic and medicinal tool in depression treatment: A review. Curr Neuropharmacol. 2022;20(6):1073-1092. PMID: 34544345.
27. Dalavaye N, Nicholas M, Pillai M, Erridge S, Sodergren MH. The clinical translation of alpha-humulene: A scoping review. Planta Med. 2024;90(9):664-674. PMID: 38626911.
28. Menezes IO, Scherf JR, Martins AOBPB, Ramos AGB, Quintans JSS, Coutinho HDM, Ribeiro-Filho J, de Menezes IRA. Biological properties of terpinolene evidenced by in silico, in vitro and in vivo studies: A systematic review. Phytomedicine. 2021;93:153768. PMID: 34634744.
29. Russo EB. Taming THC: Potential cannabis synergy and phytocannabinoid-terpenoid entourage effects. Br J Pharmacol. 2011;163(7):1344-1364. PMID: 21749363.